A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma-Reference-Cited by-同舟云学术

A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma

Published:2022-04-07 Issue:6 Volume:57 Page:1017-1020
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Liu Huimin,Liu Wei,Li Ru,Jiao Yang,Huang Wenyang,Yi Shuhua,Lv Rui,Deng Shuhui,An Gang,Wang Tingyu,Sui Weiwei,Fu Mingwei,Zhao Yaozhong,Qiu Lugui,Zou Dehui^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01655-0.pdf

Reference12 articles.

1. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012;40:800–10. https://doi.org/10.1016/j.exphem.2012.06.001

2. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transpl. 2012;18:1677–86. https://doi.org/10.1016/j.bbmt.2012.05.011. e-pub ahead of print 2012/05/31

3. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transpl. 2013;19:410–7. https://doi.org/10.1016/j.bbmt.2012.10.029. e-pub ahead of print 2012/11/07

4. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, et al. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transpl. 2018;24:1602–9. https://doi.org/10.1016/j.bbmt.2018.02.020. e-pub ahead of print 2018/03/05

5. Robinson SP, Boumendil A, Finel H, Dreger P, Sureda A, Hermine O, et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. Bone Marrow Transpl. 2018;53:1553–9. https://doi.org/10.1038/s41409-018-0196-3. e-pub ahead of print 2018/06/10

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma;Journal for ImmunoTherapy of Cancer;2024-04

2. Gemcitabine‐based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes;Cancer Medicine;2024-01

3. The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma;2023-12-08

4. Self-Healing Flexible Pressure Sensor for Human Motion Detection Based on Silver-Nanoparticle-Modified Polyimide Membranes;ACS Applied Polymer Materials;2023-07-26

5. Investigation on Low-Frequency Sound Absorption Properties of PVB Micro-/Nanofiber Membranes;Fibers and Polymers;2023-07-19